Elliot Dasenbrook, MD
Elliot Dasenbrook, MD, director of the Cleveland Clinic Adult Cystic Fibrosis Program and the Bronchiectasis Center in the Respiratory Institute, spoke with Healio about the unique challenges in treating patients with cystic fibrosis as well as current research in the field.
In this video, Dasenbrook discussed:
- The transition from pediatric to adult care for patients with cystic fibrosis, including the psychological difficulties accompanying this change and how best to prepare patients and their families for the transition;
- The management of a systemic disease such as cystic fibrosis, highlighting the importance of involving other specialists, such as endocrinologists and rheumatologists, to treat the effects of cystic fibrosis on other organs in the body;
- The benefits and drawbacks of telemedicine for patients with cystic fibrosis, especially during the COVID-19 pandemic;
- Disparities in care for different patient populations, particularly regarding easy access to specialist centers and expensive treatments;
- How to approach treatment of patients with cystic fibrosis who are not responsive to CFTR modulators, such as more aggressive treatment of symptoms and downstream effects of the disease;
- Research into treatments for patients with rare mutations, including therapies that work directly on the chloride channel that is abnormal as well as gene editing and gene replacement; and
- The challenges involved in diagnosing and treating lung infections in patients with cystic fibrosis.
Click Here to Manage Email Alerts